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improvement from baseline to week 26, in 7 of 8 SF-36 domains, versus non-re-
sponders, and 2 to 8 times greater improvement in HAQ. Patients attaining low
disease activity (Sub-group C) experienced the greatest differences. For Sub-group
B, where cohorts had the most comparable baseline scores, results were statisti-
cally significant for HAQ (p0.0012) and 6 of 8 SF-36 domains (p0.01 except role-
emotional and mental health domains). CONCLUSIONS: Patients able to attain
T2T-related response achieved significantly greater absolute improvement in
health status versus non-responders, in HAQ and 6 of 8 SF-36 domains. There may
be additional value in adding change scores to threshold values in current T2T
objectives for severe patients and consideration of patient functionality may be
warranted.
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OBJECTIVES: To describe the shared decision-making process between patients
and physicians when initiating biologic therapy for the treatment of rheumatoid
arthritis (RA) from the patient perspective. METHODS: Patients self-reporting a
diagnosis of RA completed a self-administered, internet-based questionnaire in
the Fall of 2011. A subset of patients currently using a biologic therapy to treat their
RA provided details about the decision-making process for initiating their current
therapy. RESULTS: A total of 2138 respondents (76% female, mean age 56.4) com-
pleted the questionnaire. Of these, 20% (n434) were currently being treated with
biologic therapy. Discussions about biologic therapy weremost often initiated by a
rheumatologist (91%); only a small proportion of patients reported that a primary
care physician (4%), the patient themselves (3%), or another (2%) initiated the dis-
cussion. During the discussions, physicians most often focused on administration
(77%), dosing schedule (77%), side effects (71%), safety risks (64%), importance of
long-term use (57%), and importance of concomitant methotrexate use (53%). Pa-
tients rated the following as very or extremely influential (4 or 5 on a 5-point Likert
scale) on the final decision to initiate biologic therapy: advice or recommendation
by physician (76%), co-pay assistance to cover out-of-pocket costs (31%), advice or
recommendation from other healthcare professional (28%), patient literature ma-
terials from physician office (27%), and information from general websites (22%).
Most patients (71%) reported making the decision to start biologic therapy at the
time of the initial discussion with their physician; mean time for all patients to
make a decision to start biologic therapy was 12.2 days from the time of initial
discussion. CONCLUSIONS: Rheumatologists are best positioned to ensure that
patients have the necessary information to actively engage in the shared decision-
making process for initiating biologic therapy. Future research should focus on
potential outcomes benefits of shared decision-making.
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OBJECTIVES: Remission by Boolean-based definition(all scores on the TJC and SJC-
,CRP(mg/dl), and PGA1) and by SDAI(3.3) were proposed by ACR/EULAR.Using
patient reported outcomes as anchors, this analysis validated these remission cri-
teria against traditional DAS28(using CRp2.6)remission. METHODS: Efficacy of
golimumab(GLM) was assessed in MTX-naïve RA patients(GO-BEFORE, N637),
RA patients with inadequate response to MTX (GO-FORWARD,N444) and RA
patients previously treated with biologic anti-TNF agent(s) with baseline MTX
use(GO-AFTER,N305).Pooled data from patients who received placebo
(PBO)MTX, or GLM(50or100mg)MTX,q4wks were used for this analysis.Pa-
tient reported outcomes were measured using:HAQ, SF-36 PCS and MCS, FACIT-
Fatigue, and VAS 0-10 of impact of RA on daily work productivity.Descriptive
statistics were provided for patient reported outcomes among patients in re-
mission as defined remission definitions. RESULTS: Greater proportions of pa-
tients treated with GLMMTX vs patients treated with PBOMTX achieved remis-
sion by each remission definition.In the pooled analysis,the remission rate at wk24
was the highest(20.2%)by DAS28 vs remission by SDAI(10.6%, p0.001) and remis-
sion by Boolean-based definition(8.6%p0.001).Patients with remission by DAS28
achieved normal physical function(HAQ0.5),normal SF-36PCS and MCS(50) by
67.8%,38.4%,62.2%,respectively;these parameters were numerically lower vs. pa-
tientswith remission by SDAI(81.3%,62.8%,72.1%,respectively) or by Boolean-based
definition(82.0%,63.5%,74.3%, respectively). Patients in remission by DAS28 had
higher HAQ scores(0.430.49)vs patients in remission by SDAI(0.260.41) or Bool-
ean-based criteria(0.280.44).Similar results were observed in measures of FACIT-
Fatigue and productivity VAS scores.Among MTX-naive patients in GO-BEFORE
who achieved remission by DAS28,71.3% achieved normal physical function vs
86.9% of those in remission by SDAI and 86.5% of patients in remission by Boolean-
based definition.Among anti-TNF experienced patients in GO-AFTER,62.1% of
those in remission by DAS28 achieved normal physical function vs. 65.0% of those
in remission by SDAI, and 66.7% of patients in remission by Boolean-based
definition.CONCLUSIONS:While disease remission has been adapted as a target in
the management of RA, more stringent remission criteria proposed by ACR/EULAR
can provide optimal patient-reported outcomes.
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OBJECTIVES: To examine the relationship of health care costs with baseline demo-
graphic and clinical characteristics for rheumatoid arthritis (RA) patients.
METHODS: Adult RA patients (ICD-9: 714.XX) treated with anti-tumor necrosis
factors (anti-TNFs) were identified from a large US commercial claims database
(June 2004-June 2009). Patientswho switched to another anti-TNF or escalated their
dosage were identified between the initial anti-TNF date and June 2008. Total and
RA-related health care costs were calculated during the 12-month period after
switch or dose escalation. Scatter plots and box plots were drawn to examine the
relationship between age, gender, comorbidity indexes, baseline costs and total
all-cause and RA-related health care costs. RESULTS: A total of 2587 RA patients
with a mean age of 55.9 were included in the final sample. 23.5% of these patients
were insured by Medicare and 76.5% by commercial health plans. Scatter plots
illustrate a slightly positive relationship between age and total health care costs in
the commercial population. Moreover, a stronger positive trend exists between the
Charleston Comorbidity Index (CCI) and total health care costs but not with RA-
related health care costs in the commercial population. Chronic Disease Score
(CDS) shows the same trend as CCI. A positive relationship can also be seen be-
tween baseline health care costs and follow up all-cause or RA-related costs. The
majority of observationswere clustered at the lower end of the domain.We further
examined the relationships in the patient populations treated with and without
methotrexate, and the results were similar. CONCLUSIONS: There were strong
positive relationships between baseline and follow-up health care costs among RA
patients who initiated anti-TNFs and subsequently switched to another drug or
escalated their dosage. The positive relationships between CCI and CDSweremore
prominent in the commercially-insured patient population.
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OBJECTIVES: To develop and test an ePRO system for routine collection of surgical
outcomes in a busy orthopaedic clinic. METHODS: We developed an ePRO (iPad)
version of the widely adopted Oxford Knee (OKS) and Shoulder (OSS) scores. A
multi-stage process was undertaken to ensure ePRO versus paper version equiva-
lence involving the PRO instrument developer, PROmanager, PRO translation spe-
cialists as well as surgeons and Electronic Management Record (EMR) hospital
specialists. This included, a review of the draft ePRO version; pilot-testing (cogni-
tive debriefing and usability testing) on five patients attending an outpatients clin-
ic; with pilot-tested results reviewed to ensure no issues arose during migration to
ePRO. RESULTS: The ePRO version of both questionnaires were shown, from pilot-
testing, to be easy to use. Compared with OKS and OSS paper versions, ePRO re-
sponses were all legible (an issue for some Rheumatoid patients) and complete.
ePRO completion also takes care of data entry, resulting in a dataset free of errors
that might otherwise arise. This suggested the potential for higher return rates
with reducedhandling costs. Following reviewof pilot-testing, no significant issues
were identified, so the final ePRO versionswere adopted. Secure synchronisation of
the completed ePRO results with the local EMR system proved straight-forward,
required little data cleaning and provided almost immediate feedback of outcomes
to clinicians. CONCLUSIONS: Initial results demonstrated the OKS and OSS have
been successfully migrated to the ePRO (iPad) version, with results from pilot-
testing demonstrating that the validity of the original PRO instrument is retained.
ePRO completion enters scores instantaneously on the local EMR system and as a
result routine collection of a high volume of PROs could be achieved efficiently.
This development facilitates the collection of PRO measure data within the clinic
setting, highlighting their potential to enhance patient-centred care across the
patients care pathway.
PMS55
QUALITY OF LIFE AMONG PATIENTS WITH SELF-REPORTED RHEUMATOID
ARTHRITIS: A NATIONALLY REPRESENTATIVE SAMPLE
Rappaport H
University of Louisiana at Monroe, Monroe, LA, USA
OBJECTIVES: To compare the health-related quality of life of patients with self-
reported Rheumatoid Arthritis to statistically matched patients without Rheuma-
toid Arthritis. METHODS: The study utilized a cross-sectional population-based
design, in which respondents, representing non- institutionalized adults in the
United States of ages 18 or above, were chosen from the 2006 Medical Expenditure
Panel Survey (MEPS). Respondents were included in the self-reported Rheumatoid
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